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Population studies showed that there are diﬀerences in T-lymphocytes subpopulation of normal children in diﬀerent regions, and
reference values in an area might be diﬀerent from another. This study compared the values in our population with CDC and
WHO reference values. Blood samples from 279 healthy, HIV-negative children <12 years of age were analysed for complete blood
count, CD3+, CD4+, CD8+ counts and percentages. Except for CD8%, mean values for all parameters measured signiﬁcantly
decreased with age. CD4+ counts were higher in females than males, P<. 05. Using the WHO criteria, 15.9% of subjects had low
total lymphocyte count and 20.6% had low CD4 count. Children <3 years had median CD4% lower than WHO normal values.
Our median CD4+ counts correlated with CDC values. Values used by WHO in infants are higher than ours. We suggest that our
children be assessed using CDC reference values which correlate with ours.
1.Introduction
The mature T-lymphocytes are deﬁned by the presence of
CD3, and either CD4+ or CD8+ unit antigens [1]. The
CD4+ antigen-bearing T-lymphocyte subset also known as
the T-helper cells has become popular since the advent
of the Human Immunodeﬁciency Virus (HIV) infection.
These T-lymphocytes are the primary targets of the HIV
infection because the CD4+ antigen is the primary binding
site of the HIV [2–4]. CD4+T cells serve as both essential
regulators and eﬀectors of the immune response; infection
with HIV induces a progressive loss of these cells [5].
Profound decline of these cells underlies the immunod-
eﬁciency that results in Acquired Immunodeﬁciency Syn-
drome (AIDS) [2]. The CD4+ T-cell count is the standard
for assessing the immunologic progression of the disease,
determination of need to commence antiretroviral (ARV)
treatment, chemoprophylaxis for opportunistic infections,
and for monitoring or modifying antiretroviral treatment
[6, 7].
An adult individual has about 3000 lymphocytes per
mm [3] in the peripheral blood with 70%–80% being T-
lymphocytes and 65% of these T-lymphocytes bear CD4+
antigens [8, 9]. In children, the number of circulating T-
cells increases from mid-gestation until the infant is about
6 months. This peak is followed by a gradual decline
throughout childhood until adult levels are reached by late
childhood [10]. As a result of the age-related changes in
the absolute lymphocyte numbers and thus CD4+ count,
the Centers for Disease Control and Prevention (CDC) in
classifying children into immune categories using CD4+,
produced a system based on speciﬁc age groups [11]. The
World Health Organization (WHO) has also evolved an age
speciﬁc CD4+ system for use in children [12]. In Caucasian,
Asian,andsomeAfricanpopulations,studieshavebeendone
to obtain reference values of CD4+ counts in the normal
population and from these centile charts absolute counts
have been published. These studies are not uniform in their
reports of reference CD4+ counts in normal children [13–
15]. Anglaret et al. in 1997 found that CD4+ absolute counts2 International Journal of Pediatrics
wereone-thirdhigherinHIV-infectedadultsinfrancophone
West Africa compared to their French counterparts [14].
Njoku et al. in a similar study in Jos, Nigeria also conﬁrmed
this report in Nigerian adults [16] .H o w e v e ra n o t h e rs t u d y
done in Lagos showed that Nigerian adults had lower CD4+
counts compared to the Caucasians [17].
It has been our experience in the Paediatrics HIV clinic
at Lagos University Teaching Hospital (LUTH) that most of
the HIV-infected infants and older children we managed had
profound CD4+ lymphocytopenia. While some studies had
been done to determine normal lymphocyte subpopulations
in the Nigerian adults [16–18] the authors are not aware of
any published work that has established a reference value
for CD4+ count in Nigerian children. In this study we
sought to evaluate the normal absolute lymphocyte, CD4+
and CD8 counts in apparently healthy Nigerian children;
determine the occurrence or otherwise of non-HIV-related
CD4+ lymphocytopenia; compare values obtained with age-
related values of CDC and WHO. Finally we attempted to
correlate the absolute lymphocyte counts with CD4+ counts.
2.SubjectsandMethods
The study was carried out at the well-baby and Community
Health outpatient clinics of LUTH, Idi-Araba, and a private
nursery and primary school located about 2 kilometers away.
Thesubjectswerechildrenaged12yearsandbelowwhowere
apparently well at least 2 weeks before recruitment and were
not on any medication except multivitamins, or were healthy
term neonates born to HIV-negative healthy mothers and
weighed at least 2500g at birth. Excluded were children who
were known to have sickle cell anaemia, HIV-exposed, HIV
positive,orwhohadbeenonsteroids,antituberculosisdrugs,
and systemic antifungal agents. Also excluded were children
who were obviously clinically ill including those having a
febrile illness or recovered from such less than 2 weeks before
recruitment; or neonates who had suﬀered from intrauterine
growth retardation.
Approval for the study was obtained from the hospi-
tal’s Ethical Committee and written informed consent was
obtained from the parents/caregivers. History concerning
the child’s health, haemoglobin genotype, the last episode
of febrile illness, immunizations and drugs administered to
the child in the preceding two weeks, mother’s health, and
baby’sconditionatbirthwasobtainedattimeofrecruitment.
Demographic data including age, sex, height, and weight
were also obtained.
Three hundred children were randomly selected at the
study centers and stratiﬁed equally into four age groups: 0–
28 days, 29 days–1year, >1–6 years, and >6–12 years. Three
to four milliliters of venous blood was taken from each of
the eligible subjects using potassium ethylene diamine tetra-
acetic acid (EDTA) bottles daily on Mondays to Fridays
between the hours of 10.00AM and 12 noon and were
transported to the Human Virology Laboratory of the
Nigerian Institute of Medical Research (NIMR), Yaba, where
analysesweredonewithin4hoursofarrivalatthelaboratory.
The distance between the places of collection was not more
than 4km, and it takes an average of 30 minutes to deliver
the samples to the laboratory.
The blood samples obtained were screened for HIV
antibody using HIV antibody ELISA and Western blot
electrophoresis. Thereafter all the samples had a complete
blood count done using an automated haemoanalyzer. The
following variables were determined: the total white blood
cell count (TWC) and diﬀerential white blood cells including
total lymphocyte count (TLC) and percentage lymphocyte,
the packed cell volume and haemoglobin concentration. The
CD3, CD4+, and CD8 counts and CD4 /CD8 ratio were
done on the same blood sample using FACScount) (Becton-
Dickinson Immunocytometry Systems, San Jose, CA, USA)
at the same Virology laboratory of NIMR, Yaba. The CD4
percentage was then determined by dividing the CD4 count
by the TLC multiplied by 100.
Data generated were entered into SPSS version 11. The
values obtained were then tabulated by age groups and sex.
Data analysis of frequencies, means, standard deviations,
correlation, and comparisons were done. Student’s t-test and
one-wayanalysisofvariancewereemployedtodeterminethe
relationship between the diﬀerent subpopulations. The 5th,
50th, and 95th percentile values were also determined and
the 50th percentile values were compared with set values as
determined by CDC [11] and WHO [12] criteria and the
ﬁgures were generated using Microsoft excel. The P-values
were taken to be signiﬁcant when less than .05.
3. Results
Out of the 300 samples collected, 21 (7.0%) were excluded
from analysis because of laboratory errors or faulty sample
collection. Of the remaining 279 subjects, 147 (52.7%) were
males and 132 (47.3%) females. The mean age of the subjects
was 37.8 ± 41.4 months; the mean age for males was 38.3 ±
41.7months;thatofthefemaleswas37.8 ±41.5months.The
diﬀerence in the age between the sexes was not statistically
signiﬁcant (t = 0.21 df = 277; P>. 05). All the mothers of
the 61 neonates included in the study were found to be HIV
negative. Also, all the subjects, including the neonates, were
found to be HIV negative.
The FACScount machine used in this study could not
determine CD4 count above 2000cells/μL. The CD4 count
in 45 children was greater than 2000cells/μL; 39 of whom
was subjects less than one year old, 4 were between 1 and 5
years,andtheremaining2wereintheagegroup>6–12years.
However these results were all recorded as 2000cells/μL.
Table 1 showed the results of total white cell count
(TWC), total lymphocyte counts (TLC) and percentages,
CD3, CD4, and CD8 counts and percentages, and CD4:CD8
in the diﬀerent age groups. The mean values signiﬁcantly
decreased with increasing age for TWC, TLC, CD3, and CD4
counts, CD4% and CD4:CD8 ratio. When all the subjects
were considered, there was no statistical diﬀerence in these
variables between the males and the females, except in the
CD4 counts where the value was signiﬁcantly higher in
females than the males (1.40 ×109 versus 1.26 ×109; t =
−2.44, P<. 05). Also, when segregated into diﬀerent ageInternational Journal of Pediatrics 3
Table 1: Total white cell count, total lymphocytes count, subsets, and percentages for healthy children by age group.
Phenotype (cells ×103) Age group Total
0–28 days 29 days–< 1 years 1–5 years 6–12 years
TWCC n∗ = 61 (22.6) n = 62 (23.0) n = 74 (27.4) n = 73 (27.0) n = 270 (100.0)
Mean (±SD) 11.16 (3.60) 9.25 (3.18) 7.85 (2.26) 6.39 (2.13) 8.53 (3.29)
50th (5th, 95th) centiles 10.70 (5.73, 17.38) 8.95 (4.50, 16.01) 7.65 (4.75, 12.00) 6.20 (2.50, 10.43) 8.10 (4.36, 14.39)
TLC n = 61 (22.6) n = 62 (23.0) n = 74 (27.4) n = 73 (27.0) n = 270 (100.0)
Mean (±SD) 5.08 (2.02) 6.26 (2.28) 4.06 (1.34) 3.17 (1.05) 4.56 (2.04)
50th (5th, 95th) centiles 4.85 (2.52, 8.70) 6.10 (2.88, 10.75) 3.95 (2.20, 6.15) 3.10 (1.40, 4.90) 4.10 (2.20, 8.65)
% lymphocyte count n = 61 (22.6) n = 62 (23.0) n = 74 (27.4) n = 73 (27.0) n = 270 (100.0)
Mean (±SD) 47.23 (15.05) 67.61 (8.21) 51.90 (8.18) 50.76 (10.10) 54.10 (12.98)
50th (5th, 95th) centiles 46.40 (25.08, 69.88) 67.7 (55.24, 82.14) 51.90 (37.08, 64.75) 50.00 (33.81, 70.46) 54.10 (31.32, 74.88)
CD3 n = 57 (21.8) n = 62 (23.7) n = 74 (28.2) n = 69 (26.3) n = 262 (100.0)
Mean (±SD) 2.59 (0.73) 2.44 (0.81) 2.19 (0.69) 1.94 (0.66) 2.27 (0.76)
50th (5th, 95th) centiles 2.50 (1.44, 3.50) 2.37 (0.98, 3.50) 2.18 (1.14, 3.49) 1.85 (0.79, 3.32) 2.21 (1.04, 3.50)
CD4 n = 57 (21.8) n = 62 (23.7) n = 74 (28.2) n = 69 (26.3) n = 262 (100.0)
Mean (±SD) 1.66 (0.35) 1.49 (0.44) 1.16 (0.43) 1.08 (0.42) 1.33 (0.47)
50th (5th, 95th) centiles 1.76 (1.11, 2.00) 1.53 (0.64, 2.00) 1.05 (0.57, 2.00) 1.00 (0.39, 1.85) 1.28 (0.58, 2.00)
CD4 percentage n = 55 (21.7) n = 58 (22.8) n = 74 (29.1) n = 67 (26.4) n = 254 (100.0)
Mean (±SD) 35.93 (9.03) 26.58 (6.23) 29.19 (8.17) 33.81 (8.10) 31.27 (8.67)
50th (5th, 95th) centiles 35.71(22.65, 50.14) 26.06 (18.50, 43.94) 28.26 (17.27, 44.95) 34.33 (19.47, 48.78) 30.09 (18.96, 46.66)
CD8 count n = 57 (21.8) n = 62 (23.7) n = 74 (28.2) n = 69 (26.3) n = 262 (100.0)
Mean (±SD) 0.74 (0.30) 0.80 (0.42) 0.84 (0.38) 0.67 (0.31) 0.76 (0.36)
50th (5th, 95th) centiles 0.72 (0.32, 1.23) 0.72 (0.21, 1.61) 0.77 (0.35, 1.61) 0.63 (0.19, 1.44) 0.69 (0.32, 1.57)
CD8 Percent n = 55 (21.7) n = 58 (22.8) n = 74 (29.1) n = 67 (26.4) n = 254 (100.0)
Mean (±SD) 15.07 (4.51) 13.47 (4.37) 20.74 (6.51) 20.99 (6.60) 17.92 (6.58)
50th (5th, 95th) centiles 14.32 (9.20, 24.35) 13.67 (7.22, 21.05) 20.74 (10.17, 30.25) 20.70 (11.87, 30.32) 17.20 (8.70, 29.25)
CD4:CD8 n = 57 (21.8) n = 62 (23.7) n = 74 (28.2) n = 69 (26.3) n = 262 (100.0)
Mean (±SD) 2.54 (1.06) 2.24 (1.15) 1.57 (0.70) 1.72 (0.62) 1.98 (0.97)
50th (5th, 95th) centiles 2.36 (1.33, 4.18) 2.10 (1.07, 3.51) 1.49 (0.69, 2.89) 1.68 (0.82, 2.89) 1.81 (0.84, 3.51)
Note: n∗ Subjects with missing values were excluded, TWCC: Total White Cell Count, TLC: Total Lymphocyte Count.
groups there were no statistically signiﬁcant diﬀerences in
the values of the measured variables between males and
females except in the age group 6–12 years where the mean
t o t a ll y m p h o c y t ec o u n t( 2 . 9 6v e r s u s3 . 4 3×109; t =− 2.04,
P<. 05), CD4 cell count (0.95 versus 1.25 ×109; t =− 3.28,
P<. 05), CD4 percentage (31.90 versus 36.17; t =− 2.21, P<
.05) and the CD4:CD8 ratio (1.46 versus 2.06; t =− 4.43,
P<. 001) were signiﬁcantly higher in the females (Table 2).
ThetotallymphocytecountwasalsocorrelatedwiththeCD4
counts, adjusting for the age of the subjects. There was high
correlation between the total lymphocyte count and CD4
count in the study, r = 0.65, P<. 001
The subjects were further rearranged into the WHO and
CDCagegroupandset-valuesforTLC,CD4count,andCD4
percentages. Using the WHO criteria for TLC, 43 (15.9%)
had values considered to be low, 30 (69.8%) of whom were
less than 1 year. For CD4 count, 54 (20.6 %) had CD4 in
the range considered to be low. Fifty-one (94.4%) of these
were less than one year of age and the remaining 3 (5.6%)
were in the age group 12–35 months. For CD4 percentage,
55.9% were normal while 12.5% were in the very low range
(Table 3).
When compared with CDC set values, 172 (65.6%) had
CD4 count in the normal range while 5 (2.0%) had values
considered to be very low. Four of these ﬁve were less than
1 year of age. Also 188 (74%) had CD4 percent values
considered normal. Only 3 (1.2 %) had values regarded to be
very low. These 3 were in the age range 1–5 years (Table 4).
The WHO and CDC age determined CD4 count and
CD4 percent were compared with the 50th percentiles for
age in this study. Since WHO CD4 percent for children older
than 5 years was not stated but was expressed as CD4 count
the value of 25% was used for children older than 5 years for
purpose of comparison.
The 50th percentile CD4 percent by age in this study
was found to be signiﬁcantly lower than the set values by
WHO in the age group ≤11 months (35% for WHO versus
28.8% in our study) and 12–35 months (30% WHO versus
25.9% in our study), respectively. However the values were
higher in the age groups 36–59 months (25% WHO versus
28.3% in the study) and ≥5 years (25% WHO versus 34.3%
in the study) (Figure 1). Conversely the comparisons of the
50th percentile for CD4 percent in this study were found
to be signiﬁcantly higher than the set points for CDC in all4 International Journal of Pediatrics
Table 2: Distribution of T-lymphocyte subsets by gender and age group.
Lymphocyte subsets
Age groups by gender
0–28 days 29 days–<1 year 1–5 years 6–12 years
Male Female Male Female Male Female Male Female
TLC (μL ×109)
Number (%) 31 (11.5) 30 (11.1) 30 (11.1) 32 (11.9) 38 (14.1) 36 (13.3) 40 (14.8) 33 (12.2)
Mean ± SD 5.26 (2.25) 4.95 (1.76) 5.78 (2.23) 6.71 (2.27) 4.24 (1.29) 3.88 (1.38) 2.96 (0.91) 3.43 (1.07)
Median 4.90 4.55 5.40 6.20 4.35 3.70 2.85 3.40
CD4 count (μL ×109)
Number (%) 30 (11.5) 27 (10.3) 31 (11.8) 31 (11.8) 38 (14.5) 36 (13.7) 39 (14.9) 30 (11.5)
Mean ± SD 1.64 (0.37) 1.69 (0.33) 1.41 (0.47) 1.57 (0.40) 1.17 (0.39) 1.16 (0.48) 0.95 (0.38) 1.25 (0.40)
Median 1.66 1.78 1.33 1.62 1.06 1.02 0.89 1.16
CD4%
Number (%) 28 (11.0) 27 (10.6) 28 (11.0) 30 (11.8) 38 (15.0) 36 (14.2) 37 (14.6) 30 (11.8)
Mean ± SD 35.08 (8.88) 36.80 (9.27) 27.48 (6.55) 25.75 (5.90) 28.30 (7.24) 30.13 (9.06) 31.90 (9.06) 36.17 (6.04)
Median 35.42 35.71 26.41 24.88 28.05 28.58 32.96 36.71
CD8 count (μL ×109)
Number (%) 30 (11.5) 27 (10.3) 31 (11.8) 31 (11.8) 38 (14.5) 36 (13.7) 39 (14.9) 30 (11.5)
Mean ± SD 0.73 (0.36) 0.76 (0.21) 0.79 (0.43) 0.81 (0.42) 0.88 (0.41) 0.79 (0.34) 0.69 (0.36) 0.65 (0.24)
Median 0.65 0.75 0.71 0.74 0.80 0.72 0.65 0.62
CD8%
Number (%) 28 (11.0) 27 (10.6) 28 (11.0) 30 (11.8) 38(15.0) 36 (14.2) 37 (14.6) 30 (11.8)
Mean ± SD 13.76 (3.71) 16.44 (4.90) 14.40 (4.54) 12.60 (4.08) 20.75 (6.36) 20.74 (6.74) 22.98 (7.46) 18.54 (4.35)
Median 13.53 15.34 15.47 12.04 20.33 20.54 22.48 18.72
CD4:CD8 Ratio
Number (%) 30 (11.5) 27 (10.3) 31 (11.8) 31 (11.8) 38 (14.5) 36 (13.7) 39 (14.9) 30 (11.5)
Mean ± SD 2.70 (1.28) 2.37 (0.74) 2.20 (1.42) 2.28 (0.82) 1.53 (0.71) 1.62 (0.71) 1.46 (0.52) 2.06 (0.59)
Median 2.54 2.16 2.00 2.25 1.44 1.53 1.42 2.05
Table 3: Distribution of total lymphocyte count, CD4 count, and percentage using WHO cut-oﬀ values.
Total lymphocyte
count and CD4
groupings
Age group
Total n (%) ≤11 months 12–35 months 36–59 months ≥5 years
WHO Study n (%) WHO Study n (%) WHO Study n (%) WHO Study n (%)
CD4 count
(cells/ul) n = 262 <1,500 51 (42.9) <750 3 (10.0) <350 0 <200 0 54 (20.6)
TLC (cells/ul)
n = 270
<4000
n = 123
30 (24.4) <3000
n = 30
4 (13.3) <2500
n = 33
3 (9.1) <2000
n = 84
6 (7.1) 43 (15.9)
WHO CD4 %
≥35 34 (30.1) ≥30 12 (40.0) ≥25 21 (63.6) ≥500 76 (95.0) 143 (55.9)
30–34.9 15 (13.3) 25–29.9 4 (13.3) 20–24.9 9 (27.3) 350–499 3 (3.8) 31 (12.1)
25–29.9 36 (31.8) 20–24.9 12 (40.0) 15–19.9 1 (3.0) 200–349 1 (1.2) 50 (19.5)
<25 28 (24.8) <20 2 (6.7) <15 2 (6.1) <200 or
<15%
0 32 (12.5)
age groups (28.8%, 28.3%, and 33.4% for ages <1yr, 1–5yrs,
6yrs,above,resp.).
The closest comparison was however in the CD4 count
values of CDC and the 50th percentile values in our study
where there was no statistical diﬀerences in study values and
CDC values in the age groups <1 year (1,500 CDC versus
1,624cells/μL for our study) and those between 1 and 5 years
1,000cells/μL CDC versus 1,047cells/μLf o ro u rs t u d y ) ,b u t
the value was much higher in the age group 6 years and
above (500cells/μL CDC versus 996cells/μLf o ro u rs t u d y )
(Figure 2).
However, ﬁve children, 4 of whom were less than one
year and the remaining in the age range 1–5 years, had CD4
count values less than 750 cells/μL and 500 cells/μLr e s p e c -
tively, considered to be severe immunosuppression levels
(Table 4).International Journal of Pediatrics 5
Table 4: Distribution of CD4 count by age group in study subject using CDC cut-oﬀ values.
Age group Total n (%)
< 12 months 12–71 months ≥ 6 years
CDC classiﬁcation (cells/μL)
CDC Study n (%) CDC Study n (%) CDC Study n (%)
≥1,500 68 (57.1) ≥1,000 39 (52.7) >500 65 (94.2) 172 (65.6)
750–1,499 47 (39.5) 500–999 34 (46.0) 200–499 4 (5.8) 85 (32.4)
<750 4 (3.4) <500 1 (1.3) <200 0 5 (2.0)
Total 119 (100.0) 74 (100.0) 69 (100.0) 262 (100)
CDC classiﬁcation (CD4%)
≥25 85 (75.2) ≥25 46 (62.2) >25 57 (85.1) 188 (74.0)
15–24 28 (24.8) 15–24 25 (33.8) 15–24 10 (14.9) 63 (24.8)
<15 0 <15 3 (4.0) <15 0 3 (1.2)
Total 113 (100) 74 (100.0) 67 (100.0) 254 (100)
≥5years 36–59months 12–35months ≤11months
Who normal CD4 values (%)
Study CD4 5th centile values
Study CD4 50th centile values
Study CD4 95th centile values
0
10
20
30
40
50
60
Figure 1: Comparison of median CD4 percent with the WHO nor-
mal values.
4. Discussion
This study showed that there is a wide variation between
the 5th percentile and the 95th percentile in the total white
cell, the lymphocyte counts, and its subsets in the children
studied. The variation is the widest in neonates and the
infants. Also there is a steady decline in the median counts
in the total white cell count, total Lymphocyte count, and
CD4 counts with age. These ﬁndings are in conformity
with the previous reports of haematological parameters in
children [10, 19–21]. It was observed that the CD4 cell count
was signiﬁcantly higher in the females than males in our
study. This observation was largely due to the higher levels
of CD4 cells in female children older than 5 years. This
is in agreement with some studies in Asian and European
children [19, 22–24]. However several studies in the Africans
showed that there was no signiﬁcant gender diﬀerence in the
CD4 count of children until adolescence, after which females
tend to have higher CD4 count than males [25–27]. The
reasons for this disparity is not clear but both genetic and
environmental factors may play a role.
The median CD4 percentage in this study ranged from
35.9% in the neonates to the lowest level of 26.6% in infants,
≥6years 1–5years <1year
CDC normal CD4 count (cells/uL)
Study CD4 5th centile values
Study CD4 50th centile values
Study CD4 95th centile values
0
500
1000
1500
2000
2500
Figure 2: Comparison of the median CD4+ count by age with nor-
mal CDC counts.
and then gradually rose to 33.8% at 6–12 years. These values
were lower than those reported in the developed countries
[10, 22, 26] but were in agreement with ﬁndings in other
African Children [19, 27, 28]. This observed diﬀerences,
whichhad beenfoundconsistently in Africanchildren, areof
importance when CD4 percentage is to be used to determine
commencement of prophylaxis and antiretroviral therapy
in HIV-infected children. One study conducted in West
Africa observed that a CD4 percentage of 25%, with clinical
staging, provided a reliable threshold for diagnosing severe
immunosuppression and commencement of antiretroviral
therapyininfantslessthan6monthsofage[29].Itissalutary
to note that in most of the studies referred to above more
than 95 percent of the children have CD4 percentage greater
than 25%. Therefore, in the setting where virologic diagnosis
of HIV in infants less than 1 year of age is not available, the
threshold of CD4 percent of less than 25% could be a useful
tool for the commencement of ARV.
Since CD4 count or CD4% are important determinants
for commencing an HIV-infected child on antiretroviral
treatment, cut-oﬀ values for the commencement of therapy
have been determined by WHO [12] and CDC [11], and
these two organizations have important diﬀerent cut-oﬀ6 International Journal of Pediatrics
values. We therefore used these values to compare the total
lymphocyte count, CD4 counts, and percentages obtained
in this group of normal, HIV-uninfected children. Using the
WHO criteria, 54 (20.6%) of the children would have been
considered to have severe immune deﬁciency requiring the
commencement of antiretroviral therapy if they had been
HIV positive; see Tables 6 and 7. All the aﬀected children
were less than 3 years of age with majority falling below one
year. Similar scenario exists for the use of total lymphocyte
count and percentage CD4 count. Indeed, 24.8% of children
less than 1 year would have been classiﬁed as having severe
immunodeﬁciency if they were HIV positive using the WHO
criteria.
The number of children who would have been classiﬁed
as having deﬁcient levels of CD4 count was expectedly
less with CDC criteria. In this study therefore, it would
seem that the criteria used for setting the WHO cut-oﬀ
points were rather too high. Most of the studies used
by WHO in arriving at its cut-oﬀ points were derived
from developed countries. Several studies in Africa however
showed that HIV-uninfected African Children have lower
CD4 count and percentages than their European and
American counterparts [19, 27, 28]. Therefore, it might be
necessaryforWHOtoreviewitscut-oﬀpointstoreﬂectthese
diﬀerences.
It has been suggested that the CD4:CD8 ratio could be
a useful diagnostic tool in infants less than 18 months of
age where virologic testing is unavailable [30, 31]. In healthy
children, the CD8 count is about 30% of total lymphocyte
count while the CD4 count is 60% [30]. This usually gives
a CD4:CD8 ratio of greater than one. In the current study,
however, the median CD8 count was 17.2% (range 13.7% in
infants 29 days to less than one year to 20.7% in children
one year and above) of total lymphocyte count. The low
CD8% found in this study is also in keeping with the
generally low CD8 percent found in some African studies
with lower values found in infants than in older age groups
[27, 28]. The median CD4:CD8 ratio ranged from 2.36 in
the neonatal period and decreasing gradually to 1.68 in the
age group 6–12 years. This is in agreement with previous
studiesinAfricaandotherregions[24–28].Asinfectionwith
HIV destroys the CD4 cells and the immunologic system
attempts to eliminate the virus, the CD8 cells rise and CD4
cells decrease. A study done in Zimbabwe showed that a
CD4:CD8 ratio of less than one was highly predictive of
HIV infection; CD4:CD8 ratio was found to have greater
than 98% sensitivity and greater than 98% speciﬁcity in
identifying HIV-infected infants [30]. The technique was
found to be more cost-eﬀective and faster than the standard
virologic testing. Reversal of CD4:CD8 ratio in our HIV
exposed children could therefore be a useful diagnostic tool
in predicting HIV infection in HIV-exposed children who
are less than 18 months old. However, CD8 count is not
routinely done in many resource-limited countries including
our centre.
In conclusion, these ﬁndings suggest that some of the
criteria used by WHO are rather high when compared to
the values obtained in our normal children. The presence
of low CD4 count in these subjects suggests that idiopathic
low CD4 count may occur in children in our environment.
This may explain why some children who were HIV positive
but with low CD4 count remain in good health and might
not be functionally immunodeﬁcient. It is however, diﬃcult
to identify such individuals in the face of HIV infection
since their premorbid CD4 count or percentage values
would not be available for comparison. However since the
median values in this study correlate well with the set values,
especially with the CDC, we would suggest that our children
should still be assessed using these values; especially as the
recent studies are strongly pointing towards starting ART
at higher CD4 count levels for optimal beneﬁt in other to
reduce morbidity and mortality in HIV infected individuals.
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